Overview
The goal of this clinical trial is to demonstrate the commercial potential for a novel virtual reality (VR) intervention in preparation for Phase II development. This clinical trial will test the VR intervention for efficacy in reducing opioid use, increasing abstinence, and other self-reported and behavioral focus on future outcomes in individuals in early recovery from opioid use disorder.
- Will the VR group, compared to the control group, have a lower number of opioid use days?
- Will the VR group, compared to the control group, have longer periods of abstinence at the 30-day follow-up?
- Will the VR group, compared to the control group, have significantly increased opioid abstinence rates?
- Will the VR group, compared to baseline and the control group, show increased future self-identification post-VR intervention?
- Will the VR group, compared to baseline and the control group, show increased future orientation post-VR intervention?
- Will the VR group, compared to baseline and the control group, show an increased preference for delayed rewards in a laboratory delay discounting task post-VR intervention?
- Will the VR group, compared to baseline and the control group, exceed in behavioral effects (i.e., future self-identification, future orientation, and increased preference for delayed rewards) at the 30-day follow-up?
Researchers will compare the VR test group and the control group to see if there are differences in the results for the questions outlined above.
Eligibility
Inclusion Criteria:
- Abstinence between ≥14 days and ≤ 1 year
- 18-60 years old
- Verbal endorsement of commitment to recovery
- Outpatient
- Psychotropic drugs for SUD-comorbidity
- Mu-Opioid drugs
- Drug/alcohol abstinence ≥ 24 hours at the time of the study day visit
- English comprehension
Exclusion Criteria:
- Unstable medical disorders
- Outside the age range of 18-60
- Habitual drug use
- Smell/taste disorders
- Unstable psychiatric conditions
- Extravagant/elaborate face tattoos